Ifosfamide May Be Safely Used in Patients with End Stage Renal Disease on Hemodialysis by Latcha, Sheron et al.
Hindawi Publishing Corporation
Sarcoma
Volume 2009, Article ID 575629, 5 pages
doi:10.1155/2009/575629
Case Report
IfosfamideMay Be Safely Used in Patients with End Stage Renal
DiseaseonHemodialysis
Sheron Latcha,Robert G. Maki, GaryK. Schwartz, andCarlos D.Flombaum
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10065, USA
Correspondence should be addressed to Carlos D. Flombaum, ﬂombauc@mskcc.org
Received 1 May 2009; Revised 4 August 2009; Accepted 13 October 2009
Recommended by Beatrice Seddon
Background. Pharmacokinetic data on clearance of ifosfamide in hemodialysis patients are limited. Consequently, these patients
are excluded from therapy with this agent. We review the outcomes for patients at our institution with end stage renal disease
on dialysis who received ifosfamide for metastatic sarcoma. Patients and Methods. We treated three patients with end stage renal
disease on hemodialysis with escalating doses of ifosfamide. Data on radiographic response to therapy, WBC and platelet counts,
signs or symptoms of infection, neuropathy and bladder toxicity are reported. Starting doses of ifosfamide were based on review
of the literature available with subsequent modiﬁcations based on each patient’s prior exposure to myelosuppressive agents and on
symptoms of neurotoxicity and the degree of myelosuppression following each cycle of chemotherapy. Results. Myelosuppression
was the most common side eﬀect from therapy, but no patient developed a life threatening infection, neurotoxicity, or hematuria.
One patient developed epistaxis in the setting of thrombocytopenia while on warfarin therapy. All patients had clinical evidence
for therapeutic response and two had documented radiographic improvement following ifosfamide administration. Conclusion.
Ifosfamide can be used safely in combination with hemodialysis in patients with end stage renal disease.
Copyright © 2009 Sheron Latcha et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Ifosfamide has been shown to consistently achieve response
rates of at least 25% when used as a single agent in patients
withseveraltypesofrecurrentandrefractorysarcomas[1,2].
A member of the oxazaphosphorine family of alkylating
agents, ifosfamide is primarily metabolized by the liver [3].
The prodrug is transformed by cytochromes to an active
phosphoramide mustard, but also generates the urotoxin
acrolein,andtheneurotoxinandnephrotoxin,chloracetalde-
hyde. Although renal clearance in patients with normal
renal function does not usually exceed 20ml/min [4–6], and
no important pharmacokinetic changes should appear in
patients with renal impairment, an accumulation of toxic
metabolites has been observed in patients with underlying
renal insuﬃciency [7–10]. Renal excretion of some of the
nontoxic metabolites of ifosfamide, 2 and 3-dechloroethyl
ifosfamide, has been shown to account for between 4–13%
of the administered ifosfamide dose [7]. Chloracetaldehyde,
a metabolite implicated in CNS toxicity, has been shown
to accumulate in patients with renal insuﬃciency [9, 11]
and in an anephric patient on hemodialysis [12]. In vitro
studies suggest that hemodialysis can decrease ifosfamide
concentrations by 87% and chloracetaldehyde by 77% [13].
In a report of a patient who mistakenly received a rapid
infusion of 9g of ifosfamide over 1 hour, combined modality
therapy with hemodialysis and hemoperfusion decreased
serum concentrations of ifosfamide by 84% and 9%, respec-
tively [14]. To date, there are only one case report in the
world’s literature on the use of ifosfamide in an anephric
patient on hemodialysis [12] and one case report on the
use of hemodialysis to treat ifosfamide toxicity [14]. We
present our experience with three patients with end state
renal disease on hemodialysis who were treated with reduced
doses of ifosfamide, which were increased as tolerated.
2.MaterialsandMethods
After obtaining approval from our institutional review
board, we retrospectively reviewed the medical records of
three patients as outlined below.2 Sarcoma
Table 1: Dosing schedule, nadir counts and reported complications in Cases 1, 2 and 3.
Case 1
Course 1
Ifosfamide dose/m2∗ Nadir WBC (K/uL) [ANC (K/uL)] Nadir PLT (K/uL) Complication
Cycle 1 2g/m2 6.7 [4.7] 81
Cycle 2 3g/m2 3[ 2 .9] 53
Cycle 3 3g/m2 2.6 [2.3] 5 Thrombocytopenia NCI grade 4
Cycle 4 2g/m2 7[ 4 .5] 50
Cycle 5 2g/m2 6.4 [5.4] 44
Cycle 6 2g/m2 7[ 5 .3] 30
14-Month interval
Course 2
Cycle 1 2g/m2 8.9 [6.8] 35
Cycle 2 3g/m2 5 [4.6] 55
Cycle 3 3.6g/m2 2.2 [1.3] 48
Cycle 4 4g/m2 0.79 [0.26] 17 Epistaxis NCI grade 1
Case 2
Cycle 1 1.5g/m2 4.3 [3.3] 125
Cycle 2 1.8g/m2 3.8 [2.7] 115
Cycle 3 2g/m2 8 [7.4] 95
Case 3
Cycle 1 1.5g/m2 8.9 [6.3] 106 Cellulitis NCI grade 2
Cycle 2 1.8g/m2 13.7 [8.4] 334 Cellulitis NCI grade 2
∗Note: For Cases 1 and 3, this represents the total dose of ifosfamide, split over 2 consecutive days
Case 2 received a single dose of ifosfamide per cycle.
3. Results
Table 1 summarizes the dosing schedule and toxicity associ-
ated with ifosfamide administration with each of the three
cases. A graph of the WBC and platelet counts in response to
varying doses of ifosfamide used in Case 1 is represented in
Figure 1.
3.1. Case Histories
Case 1. Case 1 was a 48-year-old male who four years earlier
had been diagnosed with high grade synovial sarcoma of the
knee, metastatic to lungs. The patient was referred to the
renal service, while on hemodialysis, for consideration of the
feasibility of ifosfamide chemotherapy in a patient with end
stage renal disease. In the past, whenever chemotherapy with
this agent had been stopped, his disease recurred rapidly.
An 18-month course of ifosfamide chemotherapy became
complicated by ifosfamide nephrotoxicity and the progres-
sion to end stage renal disease, necessitating the initiation
of hemodialysis. Based on a previous report describing the
useofifosfamideadministrationinapatientonhemodialysis
(12), we decided to institute treatment with ifosfamide at
reduced doses and increased the dose as tolerated.
Chemotherapy was delivered as outlined in Table 1,C a s e
1. Hemodialysis was delivered within 10–14 hours after
the initiation of ifosfamide administration. Treatment was
initiatedatadoseof2g/m2,andwasthenincreasedto3g/m2
for the next 2 cycles. Each dose was divided evenly over two
consecutive days. Thrombocytopenia, with a nadir platelet
count of 5K/ul (NCI grade 4), was observed after the 3rd
cycle, prompting a return to 2g/m2 for all ensuing cycles
during that initial 6-month treatment period. Subsequently,
there was a 14-month period during which the patient
did not receive ifosfamide during which new lung lesions
appeared and he underwent 3 additional lung resections in
a period of 6 months.
For Course 2, ifosfamide was started at a dose of 2g/m2,
and was then increased to 3g/m2,3 . 6 g / m 2,a n dﬁ n a l l y
4g/m 2, given as split doses over 2 consecutive days. After the
4g/m 2 dose, he developed epistaxis associated with a platelet
count of 17K/uL (NCI grade 1), while on warfarin therapy
for a DVT. The details of the platelet and WBC counts with
each cycle over both courses are represented in Figure 1.
The patient expired from progression of disease 3 months
later, 7 years after the initial diagnosis of metastatic synovial
sarcoma.
Case 2. This is a 51-year old Asian female with a history of
metastatic leiomyosarcoma, who, after developing a rash on
paclitaxel, opted to be treated with Chinese herbal medica-
tions. In the setting of ureteral obstruction, her renal insuf-
ﬁciency, which was believed due at least in part to Chinese
herbal nephropathy, progressed to dialysis dependent endSarcoma 3
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Figure 1: Dose of ifosfamide with nadir platelet and white blood cell counts.
Table 2: Proposed plan for nonoliguric patients with ESRD on dialysis receiving ifosfamide.
Day 1 Admit patient in the afternoon
Forced diuresis:
Furosemide 200mg IVP over 1hour
Match urine output with D5 + 0.45%NS
(if patient oliguric/anuric, furosemide, Mesna, and IV ﬂuids are not needed)
Ifosfamide 1-2g/m2 + Mesna, starting ifosfamide at 4–6PM
Day 2 HD in the AM (10–12hrs after chemotherapy)
Repeat furosemide and IV ﬂuids as above
Ifosfamide + Mesna, starting ifosfamide at 4–6PM
stage kidney disease. Following disease progression despite
doxorubicin, the decision was made to treat with ifosfamide.
Chemotherapy was delivered as outlined in Table 1,C a s e2.
Each cycle of ifosfamide was given as one dose, three weeks
apart. Escalating doses of ifosfamide were administered over
three cycles as follows: 1.5g/m2,1 . 8g / m 2,a n d2g / m 2.T h e
ﬁrst cycle was administered as an inpatient and was followed
by hemodialysis approximately 3 hours after ifosfamide
infusion. Cycles 2-3 were given as an inpatient and the
patient then received her regular hemodialysis at her local
outpatient dialysis unit 2-3 hours later.
The patient did report some softening of her
intraabdominal masses and decreased abdominal distension
following the ﬁrst two cycles. A repeat scan done after cycle
2 showed no interval increase in tumor size. Two weeks
after the ﬁnal cycle, she reported painful neuropathy in
the left lower extremity. A consulting neurologist felt that
this presentation and distribution of symptoms was more
consistent with a plexopathy as opposed to a toxin mediated
neuropathy.Nospinalinvolvement withtumorwasnotedon
MRI or CT of the abdomen and pelvis. Imaging performed
after the third cycle showed interval decrease in the size
of some intraabdominal nodules with additional nodes
in the retroperitoneum and peritoneal cavity and new
hydronephrosis and hydroureter. Due to chronic pain and
progressive disease, the patient opted for palliative care. She
expired 8 months later.
Case 3. In December 2007, a 67-year-old male presented
with progressive metastatic myxoid/round cell liposarcoma
of the right calf, associated with increased calf pain and diﬃ-
culty with ambulation. He had received neoadjuvant therapy
with ifosfamide and doxorubicin and underwent surgical
resection of the lesion when the tumor size decreased. He
progressed to end stage kidney disease and the decision was
made to treat with ifosfamide since he had a response to this
agent in the past. Chemotherapy was delivered every 3 weeks
as outlined in Table 1,C a s e3. Dialysis was scheduled within
10 hours after the end of each dose of ifosfamide. The patient
received a starting dose of 1.5g/m2, which was increased 3
weeks later to 1.8g/m2. Both doses were split evenly over
2 days. Following both cycles, he developed cellulitis in the
aﬀected leg, NCI grade 2. After Cycle 1, the patient left the
hospital walking and his pain was well controlled. In light
of recurrent cellulitis following both cycles of ifosfamide,
the patient opted for chronic suppressive therapy with oral
antibiotics and treatment with ifosfamide was terminated.
Unfortunately, there was no repeat imaging to document
response to therapy, but the treating physician believed
he had clinical evidence of disease progression. While on
ifosfamide therapy, the patient continued to require PRBC
transfusions.
All three patients were nonoliguric. Therefore, fu-
rosemide 200mg IV was given over one hour prior to
the infusion of ifosfamide in an attempt to increase urine4 Sarcoma
ﬂow and minimize the possibility of hemorrhagic cystitis.
Mesna was given IV every 4 hours at 1/3 the ifosfamide
dose, with the ﬁrst dose 1/2 hour prior to chemotherapy.
In order to avoid overhydration, IV ﬂuids as 5% dextrose
in 0.45% saline was given at a rate equal to the urine
output.Forpatients1and3,tocoordinatethechemotherapy
administrationwithdialysis,patientswerehospitalizedinthe
afternoon and ifosfamide was administered in the evening.
Other medications administered at the time of chemother-
apy included antiemetics (granisetron, dexamethasone ,and
metoclopramide) as well as granulocyte colony stimulating
factor, given 1-2 days after completion of chemotherapy.
All three patients initially showed clinical response
following therapy with ifosfamide, though the beneﬁt was
brief in patient 3. There was radiographic evidence showing
response to treatment and lack of disease progression in
patients 1 and 2, respectively.
Myelosuppression was the most common side eﬀect
from ifosfamide treatment. Over a course of 15 total cycles,
1cycle was associated with grade 4 neutropenia and 4 cycles
with grade 3 thrombocytopenia. With regard to neurologic
sequelae, no patient developed seizures, sedation, tremors,
or irritability. Patient 2 developed neuropathic pain conﬁned
to the left lower extremity. As per a neurologist’s assessment,
based on the distribution of the pain, timing after exposure
to the alkylating agent, and MRI results, it was concluded
that the pain was most consistent with a plexopathy rather
than a toxin mediated neuropathy. Patient 3 had NCI grade
2 cellulitis. No patient developed hemorrhagic cystitis.
4. Discussion
In formulating our approach for establishing the starting
dose of ifosfamide and the timing of hemodialysis following
ifosfamide infusion, we relied heavily on the pharmacoki-
netic and toxicity data on an anephric pediatric patient on
dialysis who was treated with ifosfamide for a Wilms’ tumor
[12]. For this pediatric patient, in course 1, the patient was
given one dose of 1.6g/m2 of ifosfamide followed by dialysis
at 24 hours. Signiﬁcant neurotoxicity, including seizures,
tremors, and irritability occurred. In course 2, a dose of
1.6g/m2 was followed 72 hours later by 1g/m2.D i a l y s i sw a s
started 7 hours after each dose. This regimen produced less
neurotoxicity but more leukopenia and thrombocytopenia,
with nadir ANC and platelet counts of 440/uL and 23K/uL,
r e s p e c t i v e l y .I nc o u r s e3 ,1 g / m 2 was given every 48 hours
for 3 doses and dialysis was started at 7 hours from end
of dose. This produced neurologic toxicity comparable to
course 2 with less neutropenia and thrombocytopenia. The
nadir ANC and platelet counts were 1.2K/uL and 59K/uL,
respectively. In the last course, the patient was given four
daily doses of 1g/m2, again followed by dialysis at 7 hours
post treatment. Decreasing the interval between dosing and
increased frequency of dosing produced more neurologic
toxicity and myelosuppression. The nadir ANC and platelet
counts were 414/uL and 5K/uL, respectively.
In light of this data, in Case 1, we felt that it would be
best to begin ifosfamide therapy with approximately 2g/m2
of, divided over two consecutive days, and to then titrate
the dose and frequency of ifosfamide administration based
on clinical and laboratory parameters. A priori, we did
not know if this was an optimal dose for treatment of a
synovial sarcoma but, based on the pediatric report, wished
to avoid signiﬁcant neurotoxicity and myelosuppression.
Hemodialysis was performed 10–14 hours after ifosfamide
administration in order to allow for enough exposure to the
drug. Thereafter, the starting dose was adjusted based on
signs and symptoms suggesting neurotoxicity and the degree
and duration of myelosuppression following each cycle of
chemotherapy.
In Case 2, we referred back to the data on the anephric
patient and administered as a single dose of 1.5g/m2.
The referenced anephric patient experienced signiﬁcant
neurotoxicitywhengivenasingledoseof1.6gm/m2 followed
b yd i a l y s i sa t2 4h o u r s .T oo ﬀset the neurotoxicity observed
in course 1 with the anephric patient, and for logistical
reasons, we opted to dialyze at 3 hours instead of at 24
hours.Thisdecisionhadbeenbasedondatathatshowedthat
chloracetaldehyde, the most likely neurotoxic metabolite of
ifosfamide, had peak levels at 4 hours following ifosfamide
infusion and that chloracetaldehyde levels decreased by a
mean of 77.2% following dialysis [12]. Since our patient
receiveddialysisatanearbyoutpatientfacility,atherrequest,
dialysis was performed at her outpatient unit within 3 hours
of ifosfamide infusion for cycles 2 and 3.
Case 3 had underlying myelodysplastic syndrome. In
light of this, we decided on a lower starting dose, 1.5g/m2,
divided over 2 consecutive days, followed by dialysis within
10 hours of chemotherapy. The patient had a brief initial
clinical response to this dosing schedule with no signiﬁ-
cant myelosuppression but developed cellulitis, and clinical
disease progression, precluding further dose increments.
Ifosfamide was not administered at consistent intervals in
all cases and, with the exception of patient 1, the number of
cycles was limited.
Based on the nadir WBC and platelet counts achieved,
it appears that only Case 1 achieved a myelosuppressive
dose. Indeed, this is the only patient who experienced long
term beneﬁt from ifosfamide therapy. Unfortunately, data
on serum concentrations of ifosfamide and its metabolites
were not collected at the time of drug administration and,
because of the retrospective nature of this report, we are
unable to provide pharmacokinetic data for these 3 patients
on hemodialysis. None of the patients had the same tissue
tumor type, and it is possible that chemosensitivity of the
diﬀerentsofttissuesarcomatumortypesmayhaveanimpact
on tumor response. Only modest doses of ifosfamide were
used in these 3 cases, raising the possibility that higher doses
may have had a diﬀerent eﬀect in Cases 2 and 3 since neither
patient received myelosuppressive doses.
Although all three patients were dialysis dependent, they
did have some residual urine output and may have poten-
tially been at risk for hemorrhagic cystitis from the eﬀects of
acroleinaccumulationwithinthebladder.Althoughthereare
no data regarding the urinary excretion of this metabolite in
patients with dialysis dependent renal failure, it is possible
that the risk of hemorrhagic cystitis may be negligibleSarcoma 5
if the urotoxic metabolites are not excreted, because of
the low glomerular ﬁltration rate and resultant diminished
urine output. If this were the case, then hydration prior
to ifosfamide may not be necessary in patients who are
dialysisdependent.Sinceallwereatriskforvolumeoverload,
congestive heart failure, and hypertension if exposed to the
usual pretreatment hydration for ifosfamide administration,
we used a modiﬁed hydration protocol to mitigate bladder
toxicity and volume overload, outlined in Table 2. No patient
experienced hemorrhagic cystis or volume overload on this
protocol.
Ifosfamide, alone or in combination with other
chemotherapeutic agents, plays a signiﬁcant role in the
treatment of solid tumors. As illustrated in the ﬁrst case
scenario, this may be the only drug to which a patient
achieves sustained control of their metastatic disease. In
Case 1, the patient had 7 years of sustained response to
ifosfamide, during which time he continued to work and to
take frequent cruises. The retrospective nature of this report;
the lack of uniformity in the dose of ifosfamide and the
interval to dialysis and the absence of pharmacologic data
are all major limitations of this case report. However, given
the paucity of pharmacokinetic data on renal and dialysis
clearance of ifosfamide, and the exclusion of patients with
signiﬁcant renal insuﬃciency in clinical trials, our reported
experience does provide clinically meaningful information
for the oncologist caring for patients with severe renal
impairment.
Pharmacokinetic data on renal clearance and dialysis
clearance of ifosfamide are limited. However, the existing
data and the present case series support the use of this
alkylating agent in patients with end stage renal disease
on hemodialysis. Judicious dosing based on the combined
eﬀects of prior myelosuppressive agents and concomitant
bone marrow disease, combined with timely administration
ofhemodialysisandappropriatehydration,canavailpatients
to the therapeutic eﬀects of this agent while minimizing the
neurotoxicity, myelosuppression, and the risk for hemor-
rhagic cystitis. Moreover, with thoughtful consideration of
the dose limiting toxicity of ifosfamide, the administration
of this therapy can be modiﬁed to accommodate outpatient
hemodialysis.
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